- Home
- CNSP
as of 03-17-2026 11:04am EST
$2.30
$0.15
-6.12%
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 2.1M | IPO Year: | 2019 |
| Target Price: | $20.00 | AVG Volume (30 days): | 29.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -25.60 | EPS Growth: | -677.40 |
| 52 Week Low/High: | $0.73 - $10.59 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.09 | Index: | N/A |
| Free Cash Flow: | -17117487.0 | FCF Growth: | N/A |
AI-Powered CNSP Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 81.25%
81.25%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2024 Q1 Q1 2024 Earnings
8-K SELL May 16, 2024 · 100% conf.
2024
Q1
Q1 2024 Earnings
8-K SELLMay 16, 2024 · 100% conf.
AI Prediction SELL
1D
-5.73%
$0.21
Act: -2.08%
5D
-25.93%
$0.16
Act: -7.40%
20D
-18.99%
$0.18
Act: +1159.03%
Price: $0.22 Prob +5D: 0% AUC: 1.000
0001683168-24-003550
false 0001729427
0001729427
2024-05-16 2024-05-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 16, 2024
CNS Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Nevada 001-39126 82-2318545
(State or other jurisdiction of
incorporation or organization)
(Commission File Number) (I.R.S. Employer Identification No.)
2100 West Loop South, Suite 900
Houston, Texas 77027
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (800) 946-9185
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbols(s) Name of each exchange on which registered
Common stock, par value $0.001 per share
CNSP
The NASDAQ Stock Market LLC
Item 2.02. Results of Operations and Financial Condition.
On May 16, 2024, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01.Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit Description
99.1 Press release dated May 16, 2024
104 Cover page Interactive Data File (embedded within the Inline XBRL document)
2
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CNS Pharmaceuticals, Inc.
By: /s/ Chris Downs
Chris Downs
Chief Financial Officer
Dated: May 16, 2024
3
2024 Q1 Q1 2024 Earnings
8-K SELL Apr 1, 2024 · 100% conf.
2024
Q1
Q1 2024 Earnings
8-K SELLApr 1, 2024 · 100% conf.
AI Prediction SELL
1D
-5.73%
$0.21
Act: -2.08%
5D
-25.93%
$0.16
Act: -7.40%
20D
-18.99%
$0.18
Act: +1159.03%
Price: $0.22 Prob +5D: 0% AUC: 1.000
0001683168-24-002033
8-K
false 0001729427
0001729427
2024-04-01 2024-04-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 1, 2024
CNS Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Nevada 001-39126 82-2318545
(State or other jurisdiction of
incorporation or organization)
(Commission File Number) (I.R.S. Employer Identification No.)
2100 West Loop South, Suite 900
Houston, Texas 77027
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (800) 946-9185
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbols(s) Name of each exchange on which registered
Common stock, par value $0.001 per share
CNSP
The NASDAQ Stock Market LLC
Item 2.02 Results of Operations and Financial Condition.
On April 1, 2024, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2023 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01.Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit Description
99.1 Press release dated April 1, 2024
104 Cover page Interactive Data File (embedded within the Inline XBRL document)
2
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CNS Pharmaceuticals, Inc.
By: /s/ Chris Downs
Chris Downs
Chief Financial Officer
Dated: April 1, 2024
3
2023 Q3 Q3 2023 Earnings
8-K Nov 15, 2023
2023
Q3
Q3 2023 Earnings
8-KNov 15, 2023
0001683168-23-008159
false 0001729427
0001729427
2023-11-15 2023-11-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 15, 2023
CNS Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Nevada 001-39126 82-2318545
(State or other jurisdiction of
incorporation or organization)
(Commission File Number) (I.R.S. Employer Identification No.)
2100 West Loop South, Suite 900
Houston, Texas 77027
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (800) 946-9185
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbols(s) Name of each exchange on which registered
Common stock, par value $0.001 per share
CNSP
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.Results of Operations and Financial Condition.
On November 15, 2023, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the period ended September 30, 2023 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Exhibit Description
99.1 Press release dated November 15, 2023
104 Cover page Interactive Data File (embedded within the Inline XBRL document)
2
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CNS Pharmaceuticals, Inc.
By: /s/ Chris Downs
Chris Downs
Chief Financial Officer
Dated: November 15, 2023
3
Latest CNS Pharmaceuticals Inc. News
CNSP Breaking Stock News: Dive into CNSP Ticker-Specific Updates for Smart Investing
Compare CNSP vs Leading Stocks
See how CNSP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CNSP CNS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.